AI-powered autonomous research agents to be deployed in support of PEX010 clinical development strategy, leveraging Kala Bio’s purpose-built agentic AI platform for the biotechnology industry TORONTO and ARLINGTON, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) (“Red Light” or the “Company”) and Kala Bio, Inc. (NASDAQ: KALA) (“Kala Bio”) today announced that Red Light has engaged Kala Bio’s with its Researgency.ai agentic artificial intelligence platf ...

Core Viewpoint - Red Light Holland Corp. has engaged Kala Bio's Researgency.ai platform to enhance the clinical development strategy for its psilocybin drug candidate PEX010, aiming to leverage AI for improved research capabilities and accelerated drug development timelines [1][3][7]. Group 1: Company Developments - Red Light has entered a definitive arrangement agreement to acquire Filament Health Corp., which includes a portfolio of 76 issued patents across 15 patent families, significantly enhancing its intellectual property in botanical psilocybin drug development [2]. - PEX010 is currently supplied to over 70 clinical research sites globally and is being studied for various mental health conditions, including alcohol use disorder and treatment-resistant depression [4][8]. - The drug candidate has received authorization for clinical trials from both Health Canada and the U.S. Food and Drug Administration, demonstrating positive Phase 2 clinical data in alcohol use disorder [5]. Group 2: Strategic Rationale - The integration of the Researgency.ai platform is a strategic move for Red Light to enhance its psychedelic drug development capabilities, focusing on research planning, scenario simulation, and protocol optimization [3][6]. - The Researgency.ai platform is designed to create autonomous research loops that can generate and optimize study scenarios, compressing timelines and expanding viable options for clinical trials [6][11]. Group 3: Management Commentary - Management emphasizes that utilizing Kala Bio's AI platform is a natural progression in building a leading psychedelic drug development operation, aiming to strengthen study designs and accelerate decision-making processes [7]. - The CEO of Filament Health highlights the importance of advanced analytical tools in evaluating clinical development strategies as the program evolves [7]. - Kala Bio's CEO notes that the deployment of Researgency.ai addresses high-value, data-intensive challenges in psychedelic drug development, which can significantly impact clinical scenario evaluations [7].